SEC Company Response from ALNYLAM PHARMACEUTICALS, INC. (ALNY) (CIK 0001178670) (ALNY) — Dec 9, 2013
ALNYLAM PHARMACEUTICALS, INC. (ALNY) (CIK 0001178670)
Date: Dec. 9, 2013 · CIK: 0001178670 · Accession: 0001193125-13-466919
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-50743
Referenced dates: December 2, 2013
Letter
RE: Alnylam Pharmaceuticals, Inc.
Correspondence
December 9, 2013
Via EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Attention: Jeffrey P. Riedler, Assistant Director
Form 10-K for Fiscal Year Ended December 31, 2012
Filed February 19, 2013
File No. 000-50743
Ladies and Gentlemen:
Alnylam Pharmaceuticals, Inc. (the “Company”) hereby advises the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) that the Company has received the Staff’s letter dated December 2, 2013 (the “Comment Letter”), regarding the Commission’s review of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012. The Comment Letter requests that the Company respond within ten (10) business days from the date thereof, or inform the Staff of when the Company would provide a response. As discussed by Matthew Jones of the Commission with Mitchell Bloom, the Company’s outside counsel at Goodwin Procter LLP, the Company respectfully requests an extension of an additional ten (10) business days until December 31, 2013 to respond to the Comment Letter. The Company is committed to responding to the Comment Letter promptly and intends to provide a response to the Staff no later than December 31, 2013. Should you have any questions regarding the request made herein, please do not hesitate to contact me at (617) 551-8200. Thank you very much for your courtesy and cooperation in this matter.
Sincerely,
/s/ Michael P. Mason
Show Raw Text
CORRESP 1 filename1.htm Correspondence December 9, 2013 Via EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attention: Jeffrey P. Riedler, Assistant Director RE: Alnylam Pharmaceuticals, Inc. Form 10-K for Fiscal Year Ended December 31, 2012 Filed February 19, 2013 File No. 000-50743 Ladies and Gentlemen: Alnylam Pharmaceuticals, Inc. (the “Company”) hereby advises the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) that the Company has received the Staff’s letter dated December 2, 2013 (the “Comment Letter”), regarding the Commission’s review of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012. The Comment Letter requests that the Company respond within ten (10) business days from the date thereof, or inform the Staff of when the Company would provide a response. As discussed by Matthew Jones of the Commission with Mitchell Bloom, the Company’s outside counsel at Goodwin Procter LLP, the Company respectfully requests an extension of an additional ten (10) business days until December 31, 2013 to respond to the Comment Letter. The Company is committed to responding to the Comment Letter promptly and intends to provide a response to the Staff no later than December 31, 2013. Should you have any questions regarding the request made herein, please do not hesitate to contact me at (617) 551-8200. Thank you very much for your courtesy and cooperation in this matter. Sincerely, /s/ Michael P. Mason Michael P. Mason Vice President, Finance and Treasurer cc: Mitchell S. Bloom – Goodwin Procter LLP